RxDoctor Payments Data

Arisa Miller Mullins

Psychiatric/Mental Health · Des Moines, IANPI 1245786649

Payments from drug & device makers

$1,279in general payments, 2019–2025

Across 20 payments — averaging $63.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Acadia Pharmaceuticals Inc$684
  • Otsuka America Pharmaceutical, Inc.$307
  • Neurocrine Biosciences, Inc.$181
  • Novo Nordisk$66
  • Teva Pharmaceuticals USA, Inc.$23
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$18

What the payments were for

  • Consulting fees$25420%
  • Food & beverage$1,01679%
  • Education$91%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,279 in reported general payments places this provider in the 60th percentile of 443 psychiatric/mental health providers in Iowa.

See all psychiatric/mental health providers in Iowa

Medicare billing

Part B allowed, 2024
$126,580
Medicare patients
298
Services billed
1,364

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate13$60,183
RexultiBrexpiprazole18$13,227
Clozapine51$6,053
Sertraline Hcl386$6,002
Divalproex Sodium94$3,657
Buspirone Hcl162$2,561
Duloxetine Hcl72$2,501
Trazodone Hcl223$2,164
Rivastigmine13$1,471
Memantine Hcl44$1,263
Mirtazapine47$1,240
Fluoxetine Hcl78$1,169
Quetiapine Fumarate61$1,153
Risperidone66$955
Bupropion XlBupropion Hcl45$926

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$684$60,18313 claims
Otsuka America Pharmaceutical, Inc.Rexulti$307$13,22718 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 443 psychiatric/mental health providers in Iowa.

Other psychiatric/mental health in Des Moines

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →